Thorp Clay 4/A
4/A · Clearside Biomedical, Inc. · Filed Dec 19, 2022
Insider Transaction Report
Form 4/AAmended
Thorp Clay
Director
Transactions
- Sale
Common Stock
2021-02-10$4.43/sh−32,873$145,627→ 4,951,547 total
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on March 16, 2020.
- [F2]Consists of (i) 447 shares sold by Hatteras NC Fund, LP ("Hatteras NC"), (ii) 21,095 shares sold by Hatteras Venture Partners III, LP ("HVP III"), (iii) 1,916 shares sold by Hatteras Venture Affiliates III, LP ("HVA III") and (iv) 9,415 shares sold by Hatteras Venture Partners IV SBIC, LP ("HVP IV SBIC").
- [F3]This transaction was executed in multiple trades at prices ranging from $4.40 to $4.50, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F4]The original Form 4 inadvertently misstated the total number of shares. This reflect the accurate number of shares beneficially owned.